Modified human plasma polypeptide or Fc scaffolds and their uses

• US 8,618,257 B2
• Filed: 09/07/2007
• Issued: 12/31/2013
• Est. Priority Date: 09/08/2006
• Status: Active Grant

• Current Assignee: Ambrx, Inc. (Johnson & Johnson)
• Original Assignee: Ambrx, Inc. (Johnson & Johnson)
• Inventors: Sheffer, Joseph, Norman, Thea, Dimarchi, Richard D., Hays Putnam, Anna-Maria A., Tian, Feng, Chu, Stephanie, Krawitz, Denise, Cho, Ho Sung
• Primary Examiner(s): Bunner, Bridget E
• Assistant Examiner(s): HAMUD, FOZIA M
• Application Number:
  US12/440,010
• Publication Number:
  US 20100160212A1
• Time in Patent Office: 2,307 Days
• Field of Search: None
• US Class Current: 530/363
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/765 Serum albumin, e.g. HSA
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Modified human plasma polypeptides or Fc and uses thereof are provided.

Claims

1. A human serum albumin (HSA) comprising a non-naturally encoded amino acid at one of the following positions:

34, 82, 172, 301, 364, and 505 of SEQ ID NO;

1, linked to one or more biologically active molecules selected from the group consisting of inhibin peptides, interleukin proteins, and interleukin receptor proteins.

2. The HSA of claim 1, wherein the HSA comprises one or more post-translational modifications.

3. The HSA of claim 1, wherein the interleukin proteins are selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, and IL-12.

4. The HSA of claim 1, wherein the interleukin receptor proteins are selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, and IL-12, IL-13, IL-14, and IL-15 receptor proteins.